Vepdegestrant clinical trials
Also written ARV-471 and PF-07850327.
ClinicalTrials.gov finds 21 studies for vepdegestrant. How that becomes 23 here
Every study that search finds has been read, to see whether and how it gives vepdegestrant. ClinicalTrials.gov counts as of Nov 17, 2026. How drug pages count
- 21Found by its intervention search · See all 21 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 16 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +4Give it under a name that search misses: a biosimilar’s code or a misspelling
- 25Give vepdegestrant to participants
- −2Give it beside what is tested
- 23Test it: the count on this site
Get an email when these change. Save the vepdegestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 1 May 2026 · VEPPANU · NDA 219835 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2023 (10)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2019 | 1 |
| 2022 | 3 |
| 2023 | 10 |
| 2024 | 6 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 22 · Other 1
Pfizer (19) · Arvinas Estrogen Receptor, Inc. (2) · Arvinas Inc. (1) · QuantumLeap Healthcare Collaborative (1)
Often tested with
Tested in the same studies.
Atirmociclib (1) · Midazolam (1) · Everolimus (1) · Itraconazole (1) · Esomeprazole (1) · Carbamazepine (1) · Trastuzumab (1) · Ganitumab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 1 most studied
New when their studies opened, with vepdegestrant beside them; studies of each.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test vepdegestrant, phase 3 first.
- Dec 2026Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPhase 3 · Pfizer
- Dec 2026A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionPhase 1 · Pfizer
- Mar 2027TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Phase 1/2 · Pfizer
Studies
Open first, then newest update. How each study uses vepdegestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 23
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Alone or with letrozole or abemaciclib in endocrine pilot armsWritten as ARV-471Report a problem
- A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionRecruitingPhase 1PfizerNCT07231991Across liver impairmentWritten as vepdegestrantReport a problem
- A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called MidazolamCompletedPhase 1PfizerNCT06256510Its effect on midazolamWritten as VepdegestrantReport a problem
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)TerminatedPhase 1/2PfizerNCT05573555With ribociclib (TACTIVE-U)Written as ARV-471Report a problem
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)TerminatedPhase 1/2PfizerNCT06125522With new samuraciclib (TACTIVE-U)Written as vepdegestrantReport a problem
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingPhase 1/2PfizerNCT06206837With new atirmociclibWritten as vepdegestrantReport a problem
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedPhase 1/2Arvinas Estrogen Receptor, Inc.NCT04072952First-in-human, alone or with palbociclibWritten as VepdegestrantReport a problem
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingPhase 1/2PfizerNCT05548127With abemaciclib (TACTIVE-U)Written as ARV-471Report a problem
- A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy AdultsCompletedPhase 1PfizerNCT05930925Radiolabelled dose in healthy adultsWritten as [phenyl-14C]ARV-471Report a problem
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingPhase 3PfizerNCT05654623On the US labelAgainst fulvestrant (VERITAC-2)Written as ARV-471Report a problem
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive, not recruitingPhase 3PfizerNCT05909397With palbociclib against letrozole with palbociclib (VERITAC-3)Written as Vepdegestrant (ARV-471/PF-07850327)Report a problem
- ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast CancerCompletedPhase 1Arvinas Estrogen Receptor, Inc.NCT05501769With everolimusWritten as ARV-471 in combination with EverolimusReport a problem
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryCompletedPhase 2Arvinas Inc.NCT05549505Against anastrozole before surgery (TACTIVE-N)Written as ARV-471Report a problem
- A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy AdultsCompletedPhase 1PfizerNCT06911788Tablet against intravenous infusionWritten as Vepdegestrant (Reference)Report a problem
- A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy AdultsCompletedPhase 1PfizerNCT06645938A harder tablet against the registration tabletReport a problem
- A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaCompletedPhase 1PfizerNCT05732428Alone in advanced breast cancer, a phase 1 studyWritten as ARV-471Report a problem
- A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)Active, not recruitingPhase 1PfizerNCT05463952In Japanese patientsWritten as vepdegestrantReport a problem
- A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy AdultsCompletedPhase 1PfizerNCT06347861Registration tablets against phase 3 tabletsReport a problem
- A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy AdultsCompletedPhase 1PfizerNCT05538312How itraconazole changes its levelsWritten as vepdegestrantReport a problem
- A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy AdultsCompletedPhase 1PfizerNCT05673889Its effect on dabigatranWritten as ARV-471Report a problem
See all 23 studies that test vepdegestrant →
Behind its US label · 1 — the studies the FDA label of VEPPANU describes
From the Clinical Studies section of VEPPANU (2026-06), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 7 — no other medicine in its arm
- A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionRecruitingPhase 1PfizerNCT07231991Across liver impairmentWritten as vepdegestrantReport a problem
- A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy AdultsCompletedPhase 1PfizerNCT05930925Radiolabelled dose in healthy adultsWritten as [phenyl-14C]ARV-471Report a problem
- A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast CancerActive, not recruitingPhase 3PfizerNCT05654623On the US labelAgainst fulvestrant (VERITAC-2)Written as ARV-471Report a problem
- A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryCompletedPhase 2Arvinas Inc.NCT05549505Against anastrozole before surgery (TACTIVE-N)Written as ARV-471Report a problem
- A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy AdultsCompletedPhase 1PfizerNCT06911788Tablet against intravenous infusionWritten as Vepdegestrant (Reference)Report a problem
- A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaCompletedPhase 1PfizerNCT05732428Alone in advanced breast cancer, a phase 1 studyWritten as ARV-471Report a problem
- A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)Active, not recruitingPhase 1PfizerNCT05463952In Japanese patientsWritten as vepdegestrantReport a problem
Tested with established drugs · 6 — they are given beside it
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)TerminatedPhase 1/2PfizerNCT05573555With ribociclib (TACTIVE-U)Written as ARV-471Report a problem
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerCompletedPhase 1/2Arvinas Estrogen Receptor, Inc.NCT04072952First-in-human, alone or with palbociclibWritten as VepdegestrantReport a problem
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingPhase 1/2PfizerNCT05548127With abemaciclib (TACTIVE-U)Written as ARV-471Report a problem
- Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive, not recruitingPhase 3PfizerNCT05909397With palbociclib against letrozole with palbociclib (VERITAC-3)Written as Vepdegestrant (ARV-471/PF-07850327)Report a problem
- A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy AdultsCompletedPhase 1PfizerNCT05673889Its effect on dabigatranWritten as ARV-471Report a problem
- A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy AdultsCompletedPhase 1PfizerNCT05652660Its effect on rosuvastatinWritten as ARV-471Report a problem
Tested in a combination · 10 — another drug in the study is under test too
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Alone or with letrozole or abemaciclib in endocrine pilot armsWritten as ARV-471Report a problem
- A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called MidazolamCompletedPhase 1PfizerNCT06256510Its effect on midazolamWritten as VepdegestrantReport a problem
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)TerminatedPhase 1/2PfizerNCT06125522With new samuraciclib (TACTIVE-U)Written as vepdegestrantReport a problem
- A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.Active, not recruitingPhase 1/2PfizerNCT06206837With new atirmociclibWritten as vepdegestrantReport a problem
- ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast CancerCompletedPhase 1Arvinas Estrogen Receptor, Inc.NCT05501769With everolimusWritten as ARV-471 in combination with EverolimusReport a problem
- A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy AdultsCompletedPhase 1PfizerNCT06645938A harder tablet against the registration tabletReport a problem
- A Study to Learn How Various Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood of Healthy AdultsCompletedPhase 1PfizerNCT06347861Registration tablets against phase 3 tabletsReport a problem
- A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy AdultsCompletedPhase 1PfizerNCT05538312How itraconazole changes its levelsWritten as vepdegestrantReport a problem
- A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine VepdegestrantCompletedPhase 1PfizerNCT06275841How esomeprazole changes its levelsWritten as vepdegestrantReport a problem
- A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy ParticipantsCompletedPhase 1PfizerNCT06005688How carbamazepine changes its levelsWritten as VepdegestrantReport a problem
Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with vepdegestrant: prifetrastat 1
One option of several · 1 — a test or a strategy chooses among drugs
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped2
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)TerminatedOct 27, 2026NCT05573555
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)TerminatedOct 27, 2026NCT06125522
Codes
What other systems call vepdegestrant · ClinicalTrials.gg INT002220
- MeSH (NLM) C000732096vepdegestrantOne source NLM
- UNII (FDA) WC1U3R1YMIVEPDEGESTRANTConfirmed FDA, NLM, Wikidata
- Wikidata Q123965022vepdegestrantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C165420VepdegestrantOne source FDA
- DrugBank DB19006One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732096 | vepdegestrant | One source NLM |
| UNII (FDA) | WC1U3R1YMI | VEPDEGESTRANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123965022 | vepdegestrant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C165420 | Vepdegestrant | One source FDA |
| DrugBank | DB19006 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.